Patients with progressive multiple sclerosis (MS) 
Introduction
It has been suggested that immune-mediated mechanisms contribute to the pathogenesis of lesion formation in multiple sclerosis (MS) .' Studies ofintrablood-brain barrier IgG synthesis (1) and of expression of activation antigens on T cells derived from the systemic circulation or cerebrospinal fluid (CSF) (2) indicate a state of persistent immune activation in MS with superimposed further activity at times of "active" clinical disease. Defects in suppressor cells have been demonstrated by several assay systems to be associated with periods of clinical disease activity and are postulated to underlie the aberrant immune reactivity. The consensus from studies enumerating T5/T8 phenotypic T suppressor subsets in patients with active disease, either acute flare-ups or progressive deterioration, suggests a modest decrease in the proportion of such cells in both the systemic circulation and the CSF (3) (4) (5) (6) (7) (8) . In our studies ofin vitro pokeweed mitogen (PWM)-induced IgG secretion by peripheral blood mononuclear cells (PBMNCs) we found that reduced functional suppressor capability of the T8 cell subset rather than their proportion within 1. Abbreviations used in this paper: Con A, concanavalin A; CsA, cyclosporine A; CSF, cerebrospinal fluid; EBV, Epstein-Barr virus; E:T, effector:target ratio; IL-2, interleukin 2; MNC, mononuclear cell; MS, multiple sclerosis; NK, natural killer, PBMNC, peripheral blood MNC; PWM, pokeweed mitogen. the MNC population accounted for the high levels of in vitro IgG secretion found in the MS population (9, 10) .
Defective suppressor function in active MS has also been demonstrated by us (1 1) and others (12-14) using concanavalin A (Con A) as a suppressor cell activator. Con A-induced suppression is mediated in normals by both T8 and T4 cell subsets as well as non-T cells (15) (16) (17) (18) . Whether a failure in a specific cell subset accounts for the defective suppressor cell function in the MS population remains unclear.
The purpose ofthe present study was to evaluate suppressor and cytolytic cell functions in a rigidly defined group ofpatients with progressive MS who were being treated with cyclosporine A (CsA), a drug that is reported to selectively inhibit induction of cytolytic T cells while permitting continued generation of suppressor cells (19) (20) (21) (22) . In our studies, suppressor function was assessed using both a Con A suppressor assay and a PWM-induced IgG secretion assay.
Methods

Patients
All patients had clinical evidence ofprogressive MS for at least 2 yr, with a Kurtzke disability rating between 3 and 7 (23). These patients were studied before and while participating in a double-blind placebo-controled clinical trial of CsA as a treatment for progressive MS. No clinical correlations were made as part of this study. Patients ranged in age from 27 to 52 yr. Control donors were healthy controls ranging in age from 28 to 54 yr. CsA-treated patients received 6-8 mg/kg of the drug daily. Placebo-treated patients received the olive oil base liquid required to dissolve the CsA.
Methods
All in vitro studies were conducted on PBMNCs isolated from fresh venous blood, using a Ficoll-Hypaque gradient (Pharmacia Fine Chemicals, Piscataway, NJ). All blood samples were coded at the time ofstudy. Patients were studied in groups consisting ofat least one placebo-treated patient, one CsA-treated patient, and a control.
CON A-INDUCED SUPPRESSOR ACTIVITY. This assay was performed as previously described (11, 18) . Briefly, PBMNCs from the given donor were suspended at 106/ml in culture medium comprised of RPMI (Gibco, Grand Island, NY) with 10% fetal bovine serum plus gentamycin (0.1 mg/ml) and glutamine (4 mM). 5 In some studies, 10 and 20% by volume ofinterleukin 2 (IL-2), derived as culture supernatant from the MLA 144 Gibbon monkey tumor cell line, were added to additional cultures in flasks on day 1 of the study. IL-2 activity of the supernatants was assayed using the IL-2-dependent CTLL cell line as described by Gillis et al. (24) 
Results
Con A-induced suppressor activity. As shown in Table I , baseline suppressor activity was significantly reduced in both the CsA- In serial studies conducted on the placebo-treated MS patients, a consistent suppressor deficit, relative to control values, was observed (Table II) . When suppressor values ofCsA-treated patients were compared with those of placebo-treated patients, no significant differences were observed. No differences were noted when baseline and on-treatment values were compared. The addition of exogenous IL-2, either 10% (Table I ) or 20% (data not shown), did not enhance suppressor activity in either treated or untreated MS patients or controls. Alloantigen-directed cytolytic function. In the CsA-treated patient group, cytolytic activity (8±1%, n = 8) was markedly reduced compared with levels observed in placebo-treated patients (32±2%, n = 6, P < 0.001) and controls (31±4%, n = 4, P < 0.001). Cytolytic activity in the treated patient groups was also significantly reduced compared with their own baseline pretreatment values (7±1 vs. 25±3%, n = 5, P < 0.001). As shown in Table III , addition of 10% exogenous IL-2 restored the activity of the MS-CsA-treated patients. This effect of IL-2 on cytolytic function contrasts with the lack of augmentation of Con A suppressor activity.
PWM-induced IgG secretion (Table IV) . Levels of IgG secretion did not differ between CsA-and placebo-treated MS patients; for both MS subgroups, IgG secretion levels were higher than those found for control donors. All MS patients studied were "high" responders (9, 10).
Discussion
The results of this study indicate a reproducible defect in Con A-induced suppressor activity in patients with progressive MS. Previous studies using this assay system have documented aberrant suppressor function in MS patients with both acute flareups and progressive disease (1 1-14) . The data derived from the placebo-treated patients establishes the reproducibility and persistence ofthe finding. Previous data on patients in the recovery phase after acute flare-ups suggest that Con A-induced suppressor activity in MS can be increased at these times (1 1), and that the defective suppressor function is reversible. The lack of augmentation of Con A suppressor activity in the MS group by addition ofexogenous IL-2 to the cultures suggests that the defect is not due to failure ofIL-2 production. Conversely, the addition of IL-2 did not decrease suppressor activity in the controls, indicating that Con A suppressor activity is not a reflection of removal of IL-2 from the media as has been previously suggested (27, 28) . CsA has been reported by others to selectively spare or augment suppressor cell function while inhibiting cytolytic function (19) (20) (21) (22) . Treatment of MS patients with CsA does not restore Con A-induced suppressor activity to control values or reduce levels of PWM-induced IgG secretion, but does dramatically inhibit cytolytic cell function; this latter effect is reversed by addition of exogenous IL-2 in vitro to cultures. CsA has previously been demonstrated to inhibit IL-2 production by activated T cells. The observation that Con A-induced cell proliferation per se ([3H]thymidine uptake by PBMNCs) is not inhibited by the CsA dosages used in this study implicates a specificity of CsA for cytolytic function. With regard to the PWM-induced IgG secretion assay results, our data do not permit us to state whether CsA further inhibits suppressor function, since levels of IgG secretion in the MS group are nearly equivalent to those seen when T8V cells are completely removed from the system, i.e. cultures of purified T4' plus B(E-) cells (9, 10) .
Progressive MS patients provide a human disease model in which T8+ cell-mediated cytolytic function is preserved, whereas suppressor function, as evaluated either by a PWM-induced IgG secretion assay or by a Con A-induced suppressor cell assay, is defective (29) . In the PWM system, the T8V cell is established as the suppressor-mediating cell. T8V cells are also implicated as mediators of suppression in the Con A assay, although other cell subsets are also involved ( 17, 18) . We have found that Con A-induced suppressor activity mediated by either E+ cells isolated by rosetting techniques or by T8V cells isolated by a "panning" technique is defective in this group of MS patients. These studies were conducted in the presence ofaccessory cells (monocytes) derived from normal donors. Monocytes from the MS patients could support "normal" levels of suppression if co-cultured with normal donor E+ or T8+ cells (30). We do not, however, find a correlation between levels of Con A-induced suppression and levels of PWM-induced IgG secretion in controls. Whether the aberrant function in progressive MS reflects a single cellular mechanism remains to be defined.
The results of the present study indicate that the Con A suppressor defect is neither reversed nor augmented by CsA. Whether this combination of effects of CsA on immunologic functions will be associated with clinical efficacy of the drug awaits the results of clinical trials.
